NEW HAVEN — Biotechs Axerion Therapeutics and MedImmune have joined forces to research and develop a commercial treatment for Alzheimer’s disease.

MedImmune is the Maryland-based biologics arm of AstraZeneca, The agreement with Axerion is the first collaboration with AstraZeneca’s new Neuroscience Innovative Medicines Unit. Axerion has granted an exclusive sublicense to the company to investigate and commercialize a biological approach to binding A-beta oligimers to prion proteins. In return Axerion will receive upfront and milestone payments, plus research and development funding, as well as royalties on product sales.